OGFR Antagonist Compositions for Bone Formation Without BMP Tumor Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone formation therapies, such as BMP-based treatments, pose risks of tumor growth and are ineffective in patients with active tumors, while existing bone grafts and biologics have limitations like infection, poor healing, and high costs, making it challenging to promote bone formation without increasing tumor risk during orthopedic surgeries.
Innovation Solution
Administering an opioid growth factor receptor (OGFR) antagonist, such as naloxone or naltrexone, directly to the site of bone injury or surgery to inhibit OGFR signaling, promoting MSC differentiation into osteoblasts and reducing osteoclast activity, thereby enhancing bone formation and reducing bone degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If BMP-based therapies are used to promote bone formation, then bone formation is enhanced, but the risk of tumor growth increases
Solution Approach 1:
The patent extracts and isolates the beneficial bone-forming effect from BMP by using OGFR antagonists instead. The OGFR antagonist selectively blocks the harmful opioid growth factor signaling pathway while allowing normal bone formation mechanisms to proceed, thereby achieving bone formation enhancement without the tumorigenic side effects of BMP therapy.
Solution Approach 2:
The patent converts the harmful effect of OGFR signaling (which inhibits bone formation) into a benefit by using OGFR antagonists to block this pathway. This approach transforms a negative biological pathway into a therapeutic opportunity, achieving bone formation promotion without the harmful tumor-growth association of BMP therapies.
2Productivity
If BMP-based therapies are administered to patients with active tumors, then bone formation can be promoted, but tumor growth is exacerbated
Solution Approach 1:
The patent converts the harmful effect of OGFR signaling (which inhibits bone formation) into a benefit by using OGFR antagonists to block this pathway. This approach transforms a negative biological pathway into a therapeutic opportunity, achieving bone formation promotion without the harmful tumor-growth association of BMP therapies.
Solution Approach 2:
The OGFR antagonist serves as an intermediary that selectively blocks the harmful opioid growth factor signaling pathway while allowing normal bone formation mechanisms to proceed. This mediator approach enables bone formation enhancement in cancer patients without directly stimulating tumor growth, unlike BMP therapies.
3Productivity
If traditional bone grafts and biologics are used, then bone formation is promoted, but the risk of infection and poor healing increases
Solution Approach 1:
The OGFR antagonist therapy enables the body's own bone formation mechanisms to work more effectively by removing the inhibitory OGFR signaling barrier. This self-service approach allows endogenous osteoblasts and bone-forming cells to function at optimal capacity without introducing foreign materials that could cause infection or poor integration.
4Productivity
If OGFR antagonist is administered to promote bone formation, then bone formation and mineralization are enhanced, but the cost of treatment increases
Solution Approach 1:
The OGFR antagonist is administered as a localized, temporary therapy at the surgical site rather than requiring long-term systemic treatment. This disposable approach concentrates the therapeutic effect where needed for bone formation while avoiding the cumulative costs and side effects of prolonged treatment protocols.
Data Source
Figure 1A~1C
Figure 1D~1F
Figure 1G~1I
AI summary
This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSC) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteoradionecrosis.